Effect of *Silybum marianum* on acute hepatic damage caused by carbon tetrachloride in rats

M. Ozturk¹, M. Akdogan², I. Keskin³, A.N. Kisioglu¹, S. Oztas⁴ and K. Yildiz⁵

¹Department of Public Health, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey
²Department of Biochemistry, Faculty of Medicine, Sakarya University, Sakarya, Turkey
³Department of Histology and Embryology, Faculty of Medicine, Selcuk University, Konya, Turkey
⁴Department of Midwifery, Faculty of Health Sciences, Suleyman Demirel University, Isparta, Turkey
⁵Chairman of Public Health Laboratory, Provincial Health Directorate, Isparta, Turkey

Abstract

The study was designed to test the efficiency of *Silybum marianum* in different doses to treat carbon tetrachloride (CCl₄) induced liver damage. Thirty-five Wistar albino rats were divided randomly into five groups as follows: Control Group: 4 ml saline; CCl₄ Group: 4 ml saline plus 2 ml/kg CCl₄; 2.5% Infusion Group: 2 ml/kg CCl₄ plus 2.5% infusion of *Silybum marianum*; 5% Infusion Group: 2 ml/kg CCl₄ plus 5% infusion of *Silybum marianum*; 10% Infusion Group: 2 ml/kg CCl₄ plus 10% infusion of *Silybum marianum*. Infusions were given once a day for 5 consecutive days. CCl₄ was administered intraperitoneally (2 ml/kg) on days 2 and 3. At the end of the 5th day, animals sacrificed and their bloods were drawn for biochemical tests and liver samples were taken for histopathologic investigation. CCl₄ caused to increase in glucose and to decrease in albumin, total cholesterol and triglyceride levels. *Silybum Marianne* treatment improved these changes. All liver function tests were elevated by of CCl₄ administration and than reduced, by *Silybum Marianne* treatment. CCl₄ caused to hepatocyte degeneration, central ven dilatation, congestion, and to increase in the number of Kupffer cells and histopathological injury scores. Treatment with *Silybum marianum* infusion showed slightly preventive effect on CCl₄ induced liver damage by biochemically and histologically.

Key words: *Silybum marianum*, carbon tetrachloride, hepatic damage, hepatoprotection.

Accepted January 17 2012

Introduction

*Silybum marianum* (*Cardus marianus*), commonly known as milk thistle or St. Mary thistle or deve diken (*Turkish*), is one of the oldest and thoroughly researched plants in the treatment of liver diseases [1]. The active constituent of milk thistle is silymarin, a mixture of flavonolignans comprised of 4 isomers: silibinin, isosilibinin, silichristin, and silidianin. Most supplements are standardized according to their siliibinin (often called silybin) content, the main component of the silymarin [2]. Silymarin/silybin has been currently used for the treatment of cirrhosis, chronic hepatitis and liver diseases associated with alcohol consumption and environmental toxin exposure [3]. In the United States, milk thistle is commonly used to treat viral infections and cirrhosis of the liver [4] and the most frequently sold herbal products [2]. Phitoterapy or herbal medicine has also been used for several centuries in eastern cultures [5]. *Silybum marianum* was cited in 17th century in a medical dictionary written in Ottoman Turkish [6].

Isparta, a city in the mediterranean region of Turkey, is rich in herbal plants [7] including *Silybum marianum* used for herbal medicine. Therefore, we aimed to test hepatoprotective effect of *Silybum marianum*, grown from this region, on CCl₄ induced liver damage in rats.

Material and Methods

Animals

Adult Male Wistar albino rats weighing about 200–250 g were used in the present study. All animal fed with standard laboratory feed and water *ad libitum*. All experiments were carried out according to the guidelines for the care and use of experimental animals, and approved by the Animals Ethical Committee of Süleyman Demirel University (Number: 27.07. 2010- 01).

Drug and chemicals

Carbon tetrachloride (CCl₄), (BDH Chemicals, England) and Silybum marianum feeds (Semazen-Arzen Herbal Drug, Cosmetic and Food Company, Isparta-Turkey) were used in the experiments.
**Infusion preparation**

Boiling water (100 ml for each dose) was poured over ground seeds of *Silybum marianum* (2.5, 5 and 10 g) and left to brew for 10-15 min [8]. The cooled and filtered infusion was given to rats by gavage. Infusion was prepared daily. CCl₄ was given i.p. (2 ml/kg) to the rats.

**Animal Study Protocol**

Thirty-five animals were used in this study and divided randomly into five groups (7 animals for each). The groups were organised as follows: Control Group: 4 ml saline; CCl₄ Group: 4 ml saline plus CCl₄; 2.5% Infusion Group: CCl₄ plus 2.5% infusion of *Silybum marianum*; 5% Infusion Group: CCl₄ plus 5% infusion of *Silybum marianum* and 10% Infusion Group: CCl₄ plus 10% infusion of *Silybum marianum*. Only one of the rats in the 2.5% infusion group died during the experiment.

Saline and infusions were daily given by gavage with the amount of 4 ml. Infusions were given daily for 5 consecutive days. Two hours after the infusion treatments, 50% CCl₄ (2 ml/kg of bw) was administered intraperitoneally on days 2 and 3 [9,10]. End of the 5th day, the rats were decapitated under anesthesia (Ketamine 90 mg/kg + Xylazine 10 mg/kg). The bloods were drawn from abdominal aorta for biochemical tests. Liver was taken for histopathologic investigation.

**Biochemical Assessments**

Sera were obtained for detection of liver function tests: aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and some biochemical parameters (glucose, albumin, uric acid, urea, creatinine and total cholesterol). Olympus AU2700 autoanalyser (Japan) was used for biochemical detections by commercial kits.

**Histopathological Analysis**

The liver tissues specimens taken from the rats were fixed in Buffered Neutral Formalin 10%. The liver tissues were blocked in paraffin, sectioned at 5 - 10 microns thickness with a microtome and stained with Hematoxylin-Eosin; Microscopic images were taken with Olympus BX51 light microscope and captured digitally with Olympus DP2-BSW imaging program. The histopathological scoring of liver sections was modified from French et al. [11] as follows: 0 = no visible change/damage or; 1= mild change/damage (<25% of tissue); 2 = moderate change/damage (<25–50% of the tissue); 3 = extensive or global change/damage. The morphology of any lesions observed was interpreted according to Geller et al. [12]. Different cellular, vascular and morphological changes were evaluated. These parameters were included: sinusoidal or central ven dilatation and congestion, enlargement and inflammation of periporal area, proliferation of bile duct or Kuppfer cells, degeneration, pleomorphism and steatosis of liver cells and picnotic hepatocyte nuclei. The histopathological examinations were blinded to the study treatments.

**Statistical Analysis**

Statistical analyses were performed using the SPSS for Windows Version 9.05 program. Biochemical results were reported as mean ± standart deviation (SD) and histopathologic results were given as median (min-max). The pairwise comparisons were conducted using the “Mann-Whitney U” test. The significance level was accepted as p<0.05.

**Results**

As seen in Table 1, all liver function tests were elevated by of CCl₄ administration and reduced by *Silybum marianum* treatment. Among these reductions of the tests, only AST were significant (p<0.05) and dose dependent manner.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control (n=7)</th>
<th>CCl₄ (n=7)</th>
<th>2.5% Infusion (n=6)</th>
<th>5% Infusion (n=7)</th>
<th>10% Infusion (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (U/L)</td>
<td>139.1 ± 28.8</td>
<td>161.4 ± 34.7</td>
<td>123.5 ± 12.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>119.1 ± 8.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>143.9 ± 21.2</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>59.3 ± 3.6</td>
<td>104.0 ± 86.6</td>
<td>67.2 ± 11.1</td>
<td>57.1 ± 5.4</td>
<td>78.7 ± 33.6</td>
</tr>
<tr>
<td>ALP (U/L)</td>
<td>132.7 ± 22.8</td>
<td>141.8 ± 50.3</td>
<td>125.0 ± 37.4</td>
<td>119.4 ± 31.0</td>
<td>148.6 ± 49.1</td>
</tr>
</tbody>
</table>

<sup>Mann-Whitney U test, a: p<0.05 compared to CCl₄ group.</sup>

Biomedical Research 2012 Volume 23 Issue 2
Table 2. Some biochemical paramenters of the groups (Mean ± SD).

<table>
<thead>
<tr>
<th>Parameters*</th>
<th>Control (n=7)</th>
<th>CCl₄ (n=7)</th>
<th>2.5% Infusion (n=6)</th>
<th>5% Infusion (n=7)</th>
<th>10% Infusion (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>208 ± 30</td>
<td>265 ± 58</td>
<td>235 ± 67</td>
<td>236 ± 25</td>
<td>207 ± 57</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>3.71 ± 0.13</td>
<td>3.37 ± 0.29&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.78 ± 0.19&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.43 ± 0.17</td>
<td>3.37 ± 0.22</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.34 ± 0.08</td>
<td>0.37 ± 0.12</td>
<td>0.36 ± 0.12</td>
<td>0.31 ± .04</td>
<td>0.33 ± 0.05</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>0.74 ± 0.10</td>
<td>2.01 ± 2.18</td>
<td>1.87 ± 2.06</td>
<td>0.67 ± 0.10</td>
<td>1.26 ± 1.27</td>
</tr>
<tr>
<td>Urea (mg/dL)</td>
<td>45.57 ± 4.47</td>
<td>45.14 ± 4.85</td>
<td>37.17 ± 4.45&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40.71 ± 4.82</td>
<td>39.57 ± 5.62</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>59.02 ± 8.36</td>
<td>38.57 ± 12.27&lt;sup&gt;a&lt;/sup&gt;</td>
<td>53.83 ± 11.79</td>
<td>46.29 ± 7.74</td>
<td>46.29 ± 11.03</td>
</tr>
</tbody>
</table>

<sup>*TC: Total cholesterol. Mann-Whitney U test, a: p<0.05 compared to Control group, b: p<0.05 compared to CClᵣ group. </sup>

Table 3. Histopathological scores of liver under different doses of silymarin in rats treated with CClᵣ (Median (min-max)).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control (n=7)</th>
<th>CClᵣ (n=7)</th>
<th>2.5% Infusion (n=6)</th>
<th>5% Infusion (n=7)</th>
<th>10% Infusion (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocyte degeneration</td>
<td>0 (0-1)</td>
<td>2 (0-2)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2 (1-2)</td>
<td>1 (1-2)</td>
<td>1 (1-2)</td>
</tr>
<tr>
<td>Sinusoidal dilatation</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
<td>1 (0-1)</td>
<td>1 (0-1)</td>
<td>1 (1-1)</td>
</tr>
<tr>
<td>Central ven dilatation</td>
<td>1 (0-1)</td>
<td>2 (1-2)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1 (1-2)</td>
<td>1 (0-2)</td>
<td>0 (0-1)&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bile duct proliferation</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>Pleomorphism of liver cell</td>
<td>0 (0-0)</td>
<td>1 (0-1)</td>
<td>1 (0-2)</td>
<td>1 (0-1)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>Picnotic hepatocyte nuclei</td>
<td>0 (0-0)</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
<td>1 (0-1)</td>
<td>0 (0-0)</td>
</tr>
<tr>
<td>Periportal inflamation</td>
<td>0 (0-0)</td>
<td>1 (0-1)</td>
<td>1 (0-1)</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>Steatosis</td>
<td>0 (0-0)</td>
<td>0 (0-2)</td>
<td>1 (1-2)</td>
<td>0 (0-1)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>Increasing in the number of Kuppfer cells</td>
<td>0 (0-0)</td>
<td>1 (1-2)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1 (1-2)</td>
<td>1 (1-1)</td>
<td>1 (0-1)</td>
</tr>
<tr>
<td>Kongestion</td>
<td>0 (0-0)</td>
<td>1 (0-2)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1 (0-2)</td>
<td>1 (1-2)</td>
<td>1 (1-2)</td>
</tr>
</tbody>
</table>

<sup>Mann-Whitney U test, a: p<0.05 compared to Control group, b: p<0.05 compared to CClᵣ group. The scoring was modified as follows: 0 = no visible change/damage or; 1= mild change/damage (<25% of tissue); 2= moderate change/damage (<25–50% of the tissue); 3= extensive or global change/damage. </sup>

Although statistically insignificant, glucose and uric acid levels increased due to CClᵣ intoxication and treatment of Silybum marianum caused to decrease (Table 2). Albumin caused to be decreased by CClᵣ administration and increased by low dose Silybum marianum (p<0.05). CClᵣ did not affect kidney function tests (urea and creatinine).

Total cholesterol level was found to be significantly lowered by CClᵣ intoxication. Silybum marianum caused to slightly increase though this was not significant.

Table 3 shows histopathological scores of the groups. Administration of CClᵣ induced liver damage causing the elevated score of hepatocyte degeneration, central ven dilatation, increase in the number of Kuppfer cell, and kongestion (p<0.05). Treatment with Silybum marianum improved CClᵣ caused damages, though improvement only on central ven dilatation was significant (Figure 1).
Effect of Silybum marianum on acute hepatic damage

**Discussion**

The silymarin content in fruits of milk thistle depends on the variety and geographic and climatic conditions in which they grow. It is found at several concentrations ranging from 1 to 6% in the ripe fruit [13]. It was suggested by The European Pharmacopoeia (Ph. Eur.5.0) silymarin content should be at least 1.5% in dry drug. In our region, previous studies revealed that silymarin content was around 3% [14]. Therefore, we investigated the efficacy of different doses of *Silybum marianum* grown in our region on hepatotoxicity in rats.

In this experiment CCl$_4$ intoxication impaired liver function tests (AST, ALT and ALP) glucose and uric acid levels. Histopathologically, CCl$_4$ caused hepatocyte degeneration, central ven dilatation, increase in the number of Kupffer cell, and congestion demonstrating liver damage. Treatment with *Silybum marianum* attenuated these adverse effects.

Hepatotoxic and nephrotoxic effects of CCl$_4$ and protective effects of Silymarin were widely investigated in different models. Abdel Salam et al conducted three experiment investigating ameliorating effect of various agents comparing with silimar in on hepatic damage induced by orally administered CCl$_4$ (0.28 mL/kg). In one of their experiments [15], *Viscum album* alone or with silymarin, or silymarin alone had been orally received for 1 month, starting at the time of administration of CCl$_4$. The levels of ALT, AST, and ALP were elevated and histopathologic findings such as loss of liver tissue architecture; severe dilatation and concession of blood vessels were shown in CCl$_4$-treated rats, indicating hepatic injury. Treatment with either *Viscum album* with silymarin or silymarin alone has been biochemically and histopathologically exerted repairing effect. In their other two experiments misoprostol [16] and vinpocetine [17] were used instead of *Viscum album*. Treatment with them, alone or combination with silymarin, markedly ameliorated histopathological and biochemical alterations caused by CCl$_4$.

Suja et al. [10] also used CCl$_4$ to induce hepatic damage and used silimarin and *Helminthostachys zeylanica* (HZ) to treat it. The model was similar to our experiment. Treatment contioned 5 consecutive days and CCl$_4$ were applied on days 2 and 3. In accordance with our findings, hepatic injury induced by CCl$_4$ increased AST, ALT, ALP, bilirubin levels and caused histopathological alterations such as massive fatty changes, gross necrosis, and broad infiltration of lymphocytes and Kupffer cells around the central vein and loss of cellular boundaries. Treatment with HZ and silymarin showed similar positive effect on these changes.

---

**Figure 1.** The photomicrographs of liver section taken from rats. (A) Control group, liver cells of normal rats. (B) CCl$_4$ group, liver cells of rats intoxicated with CCl$_4$. (C) 2.5% Infusion group, Liver cells of rats treated with 2.5% infusion of *Silybum marianum* plus with CCl$_4$. 

---

A

B

C
Lee et al. [9] carried out different model than other studies to test the preventive effect of silymarin and tea seed oil (Camellia oleifera Abel.) against CCl₄-induced oxidative damage in rats. For this reason, the two agents were administrated for 6 weeks. On the last day of treatment CCl₄ were given. AST, ALT and lactate dehydrogenase (LDH) elevated because of CCl₄ intoxication. Pretreatment with silymarin and tea seed oil reduced liver function tests. They found that CCl₄ caused the lymphocytic infiltration in the central vein and fatty degeneration, necrosis, cytoplasmic vacuolization and mitosis in the hepatic cells. Treatment with tea seed oil and silymarin histologically showed preventive effect on CCl₄-induced hepatotoxicity. Like this, Merlin and Parthasarathy [18] used chloroform and ethanol extracts of Gmelina asiatica instead of tea seed oil. Silymarin was used as standard reference and exhibited significant the hepatoprotective activity against CCl₄ induced hepatotoxicity in rats.

Silymarin has also been used for the treatment of hepatotoxicity caused by agents other than CCl₄. Gopi et al. [19] constituted hepato- and nephrotoxicity by acetaminophen resulted in significant elevation of serum triglycerides, total cholesterol, blood urea nitrogen, serum creatinine, and aspartate transaminase activity. In their study, posttreatment with silymarin (25 mg/kg) significantly reversed the alterations. They had produced liver damage by giving acetaminophen in day 1-3. Then, silymarin treatment had been applied in day 4-14.

Shalan et al. [20] gave lead for 2, 4 and 6 weeks to produce liver damage. Accompanying to lead, silymarin (1 mg/100 body weigt) plus vitamin C were given three times per week. Significant lead-induced elevations in serum ALT, AST, and ALP activities had been observed after 2, 4 and 6 weeks of treatment. Dilatation and congestion of terminal hepatic veins and portal vein branches were observed after 2 weeks. Hepatocyte proliferation, portal inflammatory infiltrate with disruption of the limiting plates (interface hepatitis), steatosis, apoptosis and mild fibrosis had been detected at the end of the sixth week. Combined treatment of Vitamin C and silymarin had been shown marked improvement of the biochemical and histopathological findings.

Mansour et al. [21] made hepatotoxicity by cisplatin (CDDP) administratin, which is a widely used anticancer drug. They showed that silymarin attenuated serum ALT, AST, liver nitric oxide (NO) and malondialdehyde (MDA) level, previously increasd by CDDP. Silymarin caused to increase the activities of superoxide dismutase (SOD), glutathione peroxidase (GSHPx) reduced glutathione (GSH) and serum NO level, which were previously decreased by CDDP. Likewise, CDDP was reported to cause liver damage in high doses via involvement of oxidative stres, lipid peroxidation, and mitochondria dysfunction [22].

Shaarawy et al. [23] induced hepatic destruction by N-nitrosodiethylamine (NDEA) plus CCl₄. In their experiment, liver function enzymes and hepatic lipid peroxidation (LPO) was found to be increased and superoxide dismutase (SOD), and GSH-dependent enzymes decreased. Pradeep et al. [24] also showed that another N-nitroso alkyl compound, Diethylnitrosamine, induced alterations in the liver tissue and silymarin reversed these negative changes by improving antioxidant capacity. Protective effect of silymarin has also been shown on hepatic damage by many agents such as ethanol [25] and anti-tuberculosis drugs [26].

In this experiment, kidney function tests, BUN and creatinine, were increased by CCl₄ and reduced by silymarin though insignificant. Turgut et al. [27] showed that silymarin had a protective effect on ischemia and reperfusion injury in the kidney tissues.

We found glucose level increased by CCl₄ administration and normalized by silymarin in an insignificant manner. In similar to our findings, Vessal et al. [28] found no significant effect on blood glucose of silymarin. On the other hand, Maghrani et al. [29] showed that Silybum marianum exhibited potent hypoglycemic effects on streptozotocin-induced diabetic rats. Soto et al [30] also indicated that silymarin blunts the sustained increment in plasma glucose in alloxan-induced pancreatic damage in rats. Similarly, Huseini et al [31] showed an effective treatement of silymarin in type II diabetes patients lowering blood glucose levels.

In summary, CCl₄ administration caused hepatotoxicity and Silybum marianum treatment, though insignificant, exert protective effects. According to literature, these effects can mainly be attributed to its antioxidant effects. In accordance with our results, silymarin has clear efects in experimental animal models; however, it has not been proved effectiveness in human liver disease yet [13,32]. Another point is that, in humans, though the side effects of silymarin are uncommon, and serious toxicity has rarely been reported [13], it should be taken into account that the numbers of toxicological studies are few. Therefore, clinical and community oriented investigations to reveal possible side effects of silymarin would be usefull.

Acknowledgements

The authors thank Dr. Fatih Gultekin, Chairman of Biochemistry Department, Faculty of Medicine, Suleyman Demirel University, Isparta, for the helpful commands and constructive discussions on the manuscript, and to reading English proof.

References

Effect of Silybum marianum on acute hepatic damage


*Correspondence to:

Mustafa OZTURK
Suleyman Demirel University, School of Medicine,
Departments of Public Health
32260 Isparta
Turkey